From Principles to Practice: How Belmont Shapes What You Do at Your Site

Part of Human Subjects Protection for Clinical Research Staff: Why Human Subjects Protection Exists.

About 5 minutes. Free, in your language, no account needed.

Why this matters

Principles are easy to agree with and hard to apply at 8:30 on a busy clinic morning. This lesson connects Belmont and ICH E6(R3) to the things you will actually do: obtain consent, support risk review, and take part in deciding who is invited to join a study.

ICH E6(R3) is the international baseline in this course. The US federal regulations (HHS 45 CFR 46, FDA 21 CFR 50 and 56, HIPAA 45 CFR 164) are taught as the detailed worked example, and passages that name them are US law. Outside the United States, follow your national law and ethics committee requirements. State or local rules may add requirements.

The pairing to carry with you

Belmont's applications map to site duties:

Later modules cover each in detail. Here is a short preview of where the rules sit, in plain terms.

Consent: the rule behind respect for persons

Under 45 CFR 46.116 and 21 CFR 50.20, an investigator must obtain the legally effective informed consent of the subject, or of the subject's legally authorized representative, before involving that person in research. This is respect for persons written as a rule. Module 4 covers how to do it well.

Risk and benefit: the rule behind beneficence

The IRB must find that risks to subjects are minimized and that risks are reasonable in relation to anticipated benefits. The IRB also requires, when appropriate, adequate provisions for monitoring data to ensure subject safety. These findings appear in 45 CFR 46.111 and, for FDA-regulated research, 21 CFR 56.111. This is beneficence written as a rule.

Selection: the rule behind justice

The IRB must also determine that the selection of subjects is equitable (45 CFR 46.111(a)(3) and 21 CFR 56.111(a)(3)). This is justice written as a rule. When you help plan who is approached for a study, you are inside this standard whether or not anyone names it. A later module returns to it.

Belmont inside the regulations

The Common Rule itself points to Belmont. Under 45 CFR 46.101(c), department and agency heads exercise their judgment about coverage in a way that is consistent with the ethical principles of the Belmont Report. You do not need to remember the section number. The point is that Belmont is more than history: it is written into how the rules are meant to be applied.

ICH E6(R3): the same ideas, internationally

ICH E6(R3) is the international Good Clinical Practice (GCP) guideline. Its Principles echo the same ideas:

Look at Principle 1 once more. It puts the participant ahead of the science. If a protocol step is unsafe or unethical, "but the study needs it" is not an acceptable answer.

In practice

A coordinator receives a request from a sponsor representative to speed up enrollment by changing how people are approached. Before agreeing to anything, she asks three questions drawn from this lesson. Does this change how consent is obtained? Does it change the risks anyone faces? Does it change who is being asked?

She does not decide the answers alone. She sends the proposal to the PI, because the investigator is responsible for making sure recruitment procedures have IRB approval before they are used. The IRB, not the coordinator, decides whether the change is acceptable.

What this looks like when it goes wrong

A site team receives a protocol amendment that adds an extra blood draw and starts doing it the following week, reasoning that it is a small change. Nobody asks whether the draw changes the risk picture or the consent form.

A participant, asked to give extra blood, says she does not remember being told about it. The team treated a risk question as a scheduling question. Because consent, risk and IRB review are all connected, skipping one link left both the participant and the study exposed.

Key takeaways